Croda reports higher earnings and margins and unveils new 2028 growth targets

Croda (LSE:CRDA) delivered 2025 sales of £1.7 billion, representing growth of 6.6% at constant currency, supported by improved performance in its Consumer Care and Life Sciences divisions, both of which recorded increases in revenue, profitability and margins. Industrial Specialties, however, experienced a decline during the period. Adjusted operating profit rose 7.9% at constant currency to £295.3 million, although statutory profit was reduced by more than £100 million in impairment and restructuring charges linked to optimisation of the group’s lipids capacity as part of ongoing portfolio refinement.

Management reported that its transformation programme is progressing ahead of schedule, generating £28 million in gross benefits during 2025. The company also introduced a new working capital initiative, reduced leverage levels and modestly increased its dividend. Looking ahead, Croda outlined a new financial framework covering 2026 to 2028, targeting organic sales growth of 3–6% annually, operating margins above 20%, stronger cash generation and improved returns on capital. The strategy reflects confidence that operational efficiencies, focused innovation and enhanced customer engagement will drive performance despite an uncertain macroeconomic backdrop.

The company’s outlook combines solid financial fundamentals and strategic progress with some cautionary factors. While recent corporate developments and earnings momentum provide support, valuation remains relatively demanding and technical indicators point to weaker market momentum, suggesting investors may remain cautious in the near term.

More about Croda International

Croda International is a UK-based specialty chemicals company focused on applying “smart science” to develop high-performance ingredients and solutions across consumer care, life sciences and industrial markets. Its portfolio includes beauty and personal care actives, fragrances, home care ingredients, crop protection and seed enhancement technologies, as well as pharmaceutical components, with a strategic emphasis on higher-growth, value-added applications worldwide.